BioCryst to Present at Oppenheimer Healthcare Conference

BIRMINGHAM, Ala., Oct. 29 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals,
Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and
Chief Executive Officer of BioCryst, and Stuart Grant, Chief Financial Officer
of BioCryst, plan to provide a corporate summary at the Oppenheimer & Co.,
Inc. 20th Annual Healthcare Conference in New York on Wednesday, November 4,
2009 at 1:35 p.m. Eastern Time.

Links to a live audio Web cast and replay of the presentation may be accessed
on the BioCryst Web site at www.biocryst.com.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule
pharmaceuticals that block key enzymes involved in infectious diseases, cancer
and inflammatory diseases. BioCryst has progressed two novel compounds into
late-stage pivotal clinical trials; peramivir, an anti-viral for influenza,
and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for
cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and
structure-based drug design, BioCryst continues to discover additional
compounds and to progress others through pre-clinical and early development to
address the unmet medical needs of patients and physicians. The Company's
strategic alliances with the U.S. Department of Health and Human Services,
Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International
Holdings Limited validate its scientific foundation and the utility of its
product candidates. For more information, please visit the Company's Web site
at www.biocryst.com.

This press release contains forward-looking statements, including statements
regarding future results and achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any
future results, performances or achievements expressed or implied by the
forward-looking statements. Please refer to the documents BioCryst files
periodically with the SEC and located at
http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

SOURCE BioCryst Pharmaceuticals, Inc.

Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910